Organization
Otonomy
8 clinical trials
Clinical trial
A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's DiseaseStatus: Terminated, Estimated PCD: 2017-09-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of OTO-313 Given as a Single Intratympanic Injection in Subjects With Unilateral Subjective TinnitusStatus: Completed, Estimated PCD: 2022-06-30
Clinical trial
A Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's DiseaseStatus: Completed, Estimated PCD: 2020-12-22
Clinical trial
A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's DiseaseStatus: Terminated, Estimated PCD: 2017-09-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-413 Given as a Single Intratympanic Injection in Subjects With Speech-in-noise Hearing ImpairmentStatus: Completed, Estimated PCD: 2022-09-05
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-313 Given as a Single Intratympanic Injection in Subjects With Subjective TinnitusStatus: Completed, Estimated PCD: 2020-05-29
Clinical trial
A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's DiseaseStatus: Completed, Estimated PCD: 2017-07-18
Clinical trial
A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's DiseaseStatus: Terminated, Estimated PCD: 2017-08-31